From Nasdaq: 2024-11-22 15:00:00

Novartis upgraded its mid-term sales growth guidance. Pfizer’s hemophilia drug Hympavzi received approval from the European Commission. AstraZeneca’s Tagrisso was recommended for expanded use in EGFR-mutated lung cancer by the EU. J&J and Lilly reported positive data from mid/late-stage studies. Novartis raised its mid-term sales growth guidance, attributing it to key drug sales expectations and upcoming launches. Pfizer’s Hympavzi gained approval for treating hemophilia A and B in the EU. AstraZeneca’s Tagrisso received a recommendation for expanded use in EGFR-mutated NSCLC. J&J’s icotrokinra met goals in a pivotal plaque psoriasis study. Lilly’s muvalaplin showed promise in reducing lipoprotein(a) levels in a phase II study. The NYSE ARCA Pharmaceutical Index declined by 1.1% in the past five trading sessions. In the last five trading sessions, Lilly declined the most (4.6%), while J&J rose the most (2.4%).AbbVie rose the most in the past six months, while Novo Nordisk declined the most. AstraZeneca, Lilly, Merck, and J&J have a Zacks Rank #3 (Hold), while Pfizer has a Zacks Rank #2 (Buy). Stay tuned for more pipeline and regulatory updates in the pharma world.



Read more at Nasdaq: Pharma Stock Roundup: EU Nod for PFE’s Hympavzi, NVS Ups Sales View